Tirzepatide Cost in 2026: Brand, Vials, and Insurance Guide

How much does tirzepatide cost without insurance?

Tirzepatide is sold under two brand names by Eli Lilly, both containing the same active compound but approved for different indications. The full context for each is covered on the tirzepatide hub page. Here's what each costs at full list price.

Mounjaro (tirzepatide for type 2 diabetes)

Mounjaro was FDA-approved in May 2022 for T2D management. At full list price, a 28-day supply costs $1,112.16 (Lilly, checked October 2, 2026), regardless of dose strength. Eli Lilly prices all pen doses at the same per-pack rate, so your cost doesn't increase as you titrate up from 2.5mg to 15mg weekly. Source: Eli Lilly pricing page.

Zepbound (tirzepatide for weight management)

Zepbound received FDA approval in November 2023 for chronic weight management. Its list price is in the same range: $1,086.37 per 28-day supply as last recorded. Like Mounjaro, the pen price doesn't vary by dose strength. Source: Zepbound savings page.

List price vs. net price: what you actually pay

These list prices don't reflect reality for most patients. After manufacturer rebates and pharmacy discounts, the actual net price Lilly receives is closer to ~$520/month (~$6,236/year). A 2025 analysis in JAMA Health Forum modelled tirzepatide at this net price level and found it would need a further 30.5% reduction, to roughly $4,334/year, to meet cost-effectiveness thresholds at the $100,000-per-QALY standard used by health economists in the US [1].

For you, as a patient, the price you pay depends on which access route you use. GoodRx coupons typically bring pen pricing to $900–$1,100 at major pharmacy chains, a modest discount from list but still a substantial cash outlay.

Monthly tirzepatide costs by access route: brand pens at list price vs LillyDirect self-pay vials vs insured co-pay.

LillyDirect self-pay vials and KwikPen: a cheaper route

Eli Lilly sells Zepbound self-pay through LillyDirect, its direct-to-consumer pharmacy platform, including single-dose vials. If you're paying cash, this is almost always cheaper than buying branded pens at full list price. The vials contain the same tirzepatide molecule as Mounjaro, sold under the Zepbound name.

Pricing by dose tier

Prices are LillyDirect's Zepbound self-pay prices when you refill within 45 days (checked October 2, 2026). The KwikPen and single-dose vials carry the same self-pay prices. Without a refill inside that window, 7.5 mg costs $499 and 10 mg to 15 mg cost $699. Source: LillyDirect, Zepbound [3].

Requirements and caveats

• Prescription required: You need a valid Rx from a US-licensed prescriber. Telehealth providers (Hims, Ro, etc.) can issue prescriptions.
• Refill within 45 days: To stay eligible for programme pricing, you must refill within 45 days of your previous order. Missing this window can mean paying the higher non-programme price.
• US only: LillyDirect ships within the United States only.
• KwikPen or vial: The self-pay prices apply to both the Zepbound KwikPen (pen needles bought separately) and single-dose vials. Each vial holds a ready-to-use 0.5 mL solution (Zepbound label). It is not a powder, and nothing is mixed in. You draw the dose with a needle and syringe and inject subcutaneously.
• Cannot be combined with insurance: The self-pay vial programme is for cash-pay patients. If you have insurance coverage, you can't stack this on top of it.

Getting tirzepatide with insurance

Insurance coverage for tirzepatide varies widely depending on your plan, the approved indication (diabetes vs weight loss), and which drug is prescribed. Here's how each major coverage category works.

Commercial insurance + manufacturer savings card

If your commercial insurance plan covers Mounjaro or Zepbound, Eli Lilly's savings cards can reduce your copay to as little as $25/month for a 1–3-month supply. There is an annual cap of $1,950 per calendar year for the Mounjaro savings card. The cards are available directly through Lilly's patient savings programmes and are stackable with most commercial plans.

Prior authorisation (PA) is common. Your prescriber typically needs to document medical necessity, and many plans require you to have tried and failed other diabetes or weight management treatments first, a process called step therapy.

Medicare coverage

Medicare Part D covers tirzepatide for specific indications only:

• ✅ Mounjaro for type 2 diabetes: Covered under Medicare Part D as a diabetes medication.
• ✅ Zepbound for obstructive sleep apnoea (OSA): Covered since Zepbound's OSA approval in December 2024.
• ❌ Zepbound for obesity or weight loss alone: Not covered by Part D, which excludes weight-loss-only medications by statute. The Zepbound KwikPen is available separately through the CMS Medicare GLP-1 Bridge (see below).

Since 2025, Medicare Part D has an annual out-of-pocket cap, and it is indexed each year: $2,000 in 2025, $2,100 in 2026 and $2,400 in 2027. [11] [12] For covered indications, this caps your yearly exposure. Separately, since July 1, 2026 the CMS Medicare GLP-1 Bridge, a short-term demonstration running through December 31, 2027, covers the Zepbound KwikPen (not vials or single-dose pens) at a $50 copay for eligible Part D enrollees. [13] A broader, permanent Medicare coverage expansion for weight-loss drugs has been discussed but has not been enacted as of this writing. [10]

Medicaid

Medicaid coverage for tirzepatide is federally required for FDA-approved diabetes and OSA indications. Coverage for obesity treatment alone varies by state: some states include it, many do not. A 2024 KFF analysis found that coverage for weight-loss GLP-1s under Medicaid remains limited and inconsistent across the US [8].

Compounded tirzepatide in 2025: what changed

From 2022 through early 2025, compounded tirzepatide was widely available and significantly cheaper than the brand. During the FDA-declared drug shortage, compounding pharmacies could legally produce tirzepatide copies under a shortage exception. That exception is now over.

What ended and when

The FDA officially resolved the tirzepatide shortage and terminated the compounding exception in early 2025:

• February 18, 2025: Enforcement discretion ended for 503A compounding pharmacies (state-licensed pharmacies producing patient-specific prescriptions).
• March 19, 2025: Enforcement discretion ended for 503B outsourcing facilities (larger facilities producing compounded drugs at scale).
• May 7, 2025: A federal court in the Northern District of Texas upheld the FDA's decision, rejecting legal challenges from compounders.

This means compounding pharmacies can no longer legally produce tirzepatide as a bulk copy of Mounjaro or Zepbound under the shortage exception. Source: FDA.gov [2].

What may still exist

The practical impact: the $150–$699/month pricing that characterised the compounding market during 2023–2024 is largely no longer accessible through legitimate channels. If you were relying on compounded tirzepatide, LillyDirect self-pay (Zepbound KwikPen or vials) at $299–$449/month with a refill within 45 days is currently the most cost-comparable regulated alternative.

Tirzepatide pricing around the world

The US list price for Mounjaro is 2–4× higher than in other comparable countries. A 2024 analysis by KFF's Health System Tracker compared monthly tirzepatide list prices across nations [4]:

These are list prices, not actual patient costs. In countries with national health systems, patient co-pays may be zero or minimal. US prices reflect list; actual net prices after rebates are lower. Cross-border purchasing for personal use carries legal and safety risks.

The cross-border price gap partly explains why compounded tirzepatide attracted so much demand in the US, and why the commercial alternatives are still, for many people, financially out of reach without insurance.

Cost per milligram: how your dose affects monthly spend

The brand-name pen price is dose-agnostic: you pay roughly the same whether you're on 2.5mg or 15mg per week. But with LillyDirect vials, your dose matters. And it matters even more if you're calculating value: a lower effective dose costs less and carries fewer side effects. To turn your own vial price into a cost per month, week, and milligram, run the numbers through the tirzepatide cost calculator.

LillyDirect cost per mg by dose level

The cost-per-mg frame matters because research consistently shows that many people achieve significant weight loss well below the maximum 15mg dose. A 2025 analysis in the Journal of Managed Care & Specialty Pharmacy found tirzepatide 15mg was the most cost-efficient dose for patients targeting ≥30% body weight loss, but for patients with more modest goals, lower doses can deliver strong results at proportionally lower cost [6].

This is exactly where the GLP3 Planner tirzepatide calculator becomes useful. By modelling your plasma concentration curve at different dose levels, you can see whether your current dose is achieving steady-state coverage, or whether you could step down a level without meaningfully changing your drug exposure. For more on tirzepatide titration, the dosing guide covers the clinical escalation schedule in full.

Some users also explore microdosing tirzepatide at sub-clinical doses as a cost-reduction strategy, though evidence at very low doses is limited.

Practical ways to lower your tirzepatide cost

Depending on your situation, several strategies can materially reduce what you pay each month.

1. Apply for the manufacturer savings card

If you have commercial insurance (not Medicare or Medicaid), the Mounjaro or Zepbound savings card is the single biggest lever available. Out-of-pocket costs as low as $25/month are achievable. Apply directly through Lilly's patient savings portal. Your pharmacy will apply the card at the point of dispensing.

Manufacturer savings cards for Mounjaro and Zepbound can reduce monthly out-of-pocket costs to as low as $25 for commercially insured patients.

2. Consider LillyDirect self-pay over pharmacy pens

If you're paying cash and refill within 45 days, LillyDirect saves roughly 59 to 72% compared to the Zepbound pen list price. The KwikPen and single-dose vials are priced the same, so you can choose a pen or a needle and syringe.

3. Optimise your dose with a calculator

Staying at the lowest dose that achieves your goals is both the safest and cheapest strategy. The tirzepatide calculator shows your steady-state drug concentration at any dose level, helping you and your prescriber decide whether you need to escalate, or whether you're already there.

4. Check GoodRx for pen discounts

GoodRx coupons typically bring Mounjaro and Zepbound pen pricing to $900–$1,100 at major pharmacy chains. Less dramatic than the LillyDirect programme, but useful if vials aren't an option and you don't have insurance coverage.

5. Understand your insurance appeal rights

If your insurer denies coverage, you have the right to appeal. Denials for prior authorisation can often be overturned when your prescriber documents clinical necessity in detail, particularly for T2D or OSA indications where coverage is legally required. Ask your prescriber's office if they have a PA support team.

6. Compare tirzepatide vs semaglutide cost

Ozempic and Wegovy (semaglutide) are similarly priced at list, but insurance coverage varies. If cost is the primary driver and both are clinically suitable, a full cost comparison across options is worth doing. See our tirzepatide vs semaglutide comparison for a side-by-side breakdown.